基于网络药理学研究黄连解毒汤抗幽门螺杆菌感染作用机制

目的运用网络药理学方法预测黄连解毒汤抗Hp感染的主要有效成分、靶点及信号通路,挖掘其潜在作用机制,为后续实验研究提供依据。方法应用TCMSP筛选黄连解毒汤中黄连、黄芩、黄柏、栀子4味中药的主要有效成分及其潜在作用靶点。通过GeneCards数据库和人类孟德尔遗传数据库(OMIM)筛选Hp感染相关靶点,并取药物和疾病的交集靶点。将交集靶点导入Cytoscape 3.7.2构建有效成分和Hp感染相关靶点网络,并进行拓扑学分析。应用STRING在线分析平台构建靶蛋白相互作用(PPI)网络并进行分析。运用R语言在线检索Bioconductor平台对靶点进行GO功能富集;通过DAVID数据库对靶点进行KEGG通路富集分析。结果黄连解毒汤中共筛选出85个有效成分,主要包括槲皮素、小檗碱、山柰酚、汉黄芩素、黄芩素等。对应靶点112个,疾病相关靶点1960个,药物疾病共同靶点71个。网络中度值最高的有效成分为槲皮素,度值最高的靶点为环加氧酶1(PTGS1)。PPI网络中69个节点中度值较高的靶蛋白包括半胱氨酸蛋白酶3(CASP3)、IL6、MAPK8、原癌基因(MYC)、VEGFA、表皮生长因子受体(EGFR)等。GO功能富集分析共获得89个条目,KEGG通路富集分析共筛选12条存在显著差异的信号通路,其中发挥主要作用的有癌症通路、ErbB信号通路、p53信号通路、凋亡、黏附斑等。结论黄连解毒汤可通过多成分、多靶点、多通路发挥对Hp的治疗作用,可通过抗肿瘤机制调控胃癌进程,本研究可为其有效成分研究和抗Hp机制研究提供依据。     

精神分裂症中文诊断名再议

本文旨在探讨和推动Schizophrenia中文诊断名的更名工作。Schizophrenia目前的中文诊断名为“精神分裂症”，然而这一诊断名并未准确反映疾病情况且存在污名化问题。近年来，一些国家和地区纷纷推动Schizophrenia诊断名的变更，将诊断名更改为“统合失调症”“调弦病”“思觉失调症”等。中国大陆医学界应推动Schizophrenia新中文诊断名的命名工作，建议将Schizophrenia的诊断名从“精神分裂症”更改为“思觉失调症”。     

寿胎丸合四君子汤加减联合地屈孕酮片治疗高龄先兆流产的临床观察

目的:观察寿胎丸合四君子汤加减联合地屈孕酮片对高龄早期先兆流产患者的免疫因子、凝血及疗效观察,以探讨其作用机制。方法:将90例中医辨证为肾虚血瘀型的高龄先兆流产患者,以随机数字表法分为对照组、观察组,每组45例。两组均口服地屈孕酮片以黄体支持,对照组给予维生素E软胶囊(天然型)口服,观察组给予寿胎丸合四君子汤加减口服,两组疗程均为10 d。对比两组患者治疗前后中医证候评分、免疫因子、凝血因子变化及临床疗效。结果:治疗前两组的中医证候评分、免疫因子、凝血因子比较差异无统计学意义;与本组治疗前比较,两组患者中医证候评分均降低(P0.05),观察组辅助性T淋巴细胞(helper T lymphocyte,Th)比例,Th/Ts,D-二聚体(D-dimer,D-D),纤维蛋白原(fibrinogen,FIB)水平降低(P0.05),观察组凝血酶原时间(prothrombin time,PT),抑制性T淋巴细胞(suppressor T lymphocyte,Ts)比例增高(P0.05);治疗后与对照组比较,观察组Th比例,Th/Ts,D-D,FIB水平降低,PT,Ts比例增高(P0.05);两组自然杀伤细胞(natural killer cell,NK)比例治疗前后及组间比较差异无统计学意义。观察组总有效率为84.4%(38/45),对照组总有效率为64.4%(29/45)(χ2=4.398,P0.05)。两组患者在治疗期间未见明显不良反应。结论:寿胎丸合四君子汤加减联合地屈孕酮片可调节高龄先兆流产患者的免疫平衡及凝血功能,改善症状以及提高保胎疗效。     

四君子汤合四磨汤加减治疗出口梗阻型便秘吻合器经肛门直肠切除术后的临床疗效

目的:观察四君子汤合四磨汤加减治疗出口梗阻型便秘(OOC)吻合器经肛门直肠切除术后(STARR)的临床疗效。方法:124例患者随机按数字表法分为对照组和观察组各62例。对照组术后给予芪蓉润肠口服液,20 mL/次/,3次/d;观察组术后给予四君子汤合四磨汤加减内服,1剂/d。两组疗程均连续治疗4周,并进行8周随访。分别于手术前、治疗后2周,4周、随访8周进行便秘主要症状评分和Longo ODS评分;于手术前和治疗后4周,进行超氧化物歧化酶(SOD),丙二醛(MDA)和便秘患者生存质量自评量表(PAC-QOL)评价,并进行肛门直肠测压,记录肛管静息压(ARP),肛管最大收缩压(MSP),直肠排便压力(RSP),初始感觉阈值(FSV),排便感觉阈值(CRS)和最大耐受容量(MTV)等指标;随访记录并发症发生率、复发率和排便正常率;术后4周进行满意度评价和安全性评价。结果:治疗后4周,观察组患者临床疗效优于对照组(Z=2.096,P0.05);治疗后2周,4周和随访8周,观察组便秘主要症状积分和Longo ODS评分均低于对照组(P0.01);观察组患者ARP,FSV,FSV,CRS均低于对照组(P0.01),MSP和RSP均高于对照组(P0.01);观察组并发症发生率、复发率分别为20.97%(13/62)和4.84%(3/62),分别低于对照组的39.71%(24/62)和16.13%(10/62)(P0.05);观察组排便正常率为91.94%(57/62),高于对照组的80.65%(50/62),组间差异无统计学意义;观察组PAC-QOL总分和各因子评分均低于对照组(P0.01);观察组SOD水平高于对照组,MDA水平低于对照组(P0.01);未发现干预中药相关不良反应。结论:四君子汤合四磨汤加减用于出口梗阻型便秘STARR术后患者,可进一步减轻便秘症状和病情程度,提高生活质量,降低术后并发症发生率和复发率,并可改善肛门直肠动力学指标和氧化应激指标,提高临床疗效。     

扶正解毒抗癌方治疗晚期非小细胞肺癌的临床效果

目的:探讨扶正解毒抗癌方对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及对患者化疗后骨髓抑制的影响。方法:选取2016年1月至2019年3月滁州市第一人民医院收治的NSCLC患者100例,按照随机数字表法分为对照组和研究组,每组50例。对照组患者采用常规化疗,研究组患者在对照组的基础上加用扶正解毒抗癌方,两组患者连续治疗2个化疗周期。观察两组患者的临床疗效,分别于治疗前后测定白细胞计数、血小板计数及血红蛋白水平,比较两组患者治疗后骨髓抑制发生情况和卡氏(Karnofsky,KPS)评分的差异。结果:研究组患者的总有效率为62.00%(31/50),明显高于对照组的36.00%(18/50),差异有统计学意义(P<0.05)。治疗后,两组患者白细胞计数、血小板计数及血红蛋白水平均明显低于治疗前,但研究组患者上述指标水平明显高于对照组,差异均有统计学意义(P<0.05)。研究组患者骨髓抑制发生率为38.00%(19/50),明显低于对照组的68.00%(34/50),差异有统计学意义(P<0.05)。治疗后,研究组患者KPS评分提高率和稳定率分别为34.00%(17/50)、46.00%(23/50),明显优于对照组的14.00%(7/50)、16.00%(8/50),差异均有统计学意义(P<0.05)。结论:扶正解毒抗癌方联合常规化疗治疗晚期NSCLC的疗效显著,能够减轻患者化疗后骨髓抑制情况,提高患者生活质量。     

Effects of Total Hip Arthroplasty on Axial Alignment of the Lower Limb in Patients with Unilateral Developmental Hip Dysplasia (Crowe type IV)

BackgroundThe aim of this study was to evaluate the influence of total hip arthroplasty on axial alignment of the lower limb in adults with unilateral developmental hip dysplasia (Crowe type IV).MethodsWe retrospectively reviewed medical records of 50 adults who underwent total hip arthroplasty, in which the acetabular cup was placed in the anatomical position. The following parameters were measured before surgery, immediately after surgery, and two years later: mechanical axis deviation (MAD), tibiofemoral angle (TFA), femoral offset, hip-knee-ankle angle (HKA), mechanical lateral distal femoral angle (LDFA), mechanical medial proximal tibial angle, height of medial femoral condyle, height of lateral femoral condyle, and leg lengthening. Length of the resected femoral segment was also recorded from medical records.ResultsPreoperative MAD, TFA, HKA, and LDFA of the ipsilateral lower limb showed significant valgus deformity. MAD of the ipsilateral lower limb and valgus inclination were significantly smaller immediately after surgery than before, while TFA, HKA, femoral offset, and LDFA were significantly larger (P < 0.05). These parameters did not differ significantly between immediately after surgery and two years later (P > 0.05). Ipsilateral extremities were extended by a mean of 2.54 cm (range, 0 to 5.35 cm). The mean length of the femoral resected segment was 3.56 cm (range, 2.03 to 5.74 cm). The contralateral lower limb showed marginally smaller MAD and medial proximal tibial angle after surgery than before, but larger LDFA, TAF, and HKA.ConclusionsIn patients with developmental hip dysplasia who underwent total hip arthroplasty with placement of the acetabular component at the level of the anatomic hip center, axial alignment of the ipsilateral lower limb was immediately altered, and valgus inclination was significantly reduced. The procedure only slightly altered the axial alignment of the contralateral lower limb.     

Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors

BackgroundWe aimed to develop a modified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model that can predict early death less than 1 year in patients with metastatic renal cell carcinoma (mRCC) after receiving first-line tyrosine kinase inhibitors (TKIs).Patients and MethodsWe retrospectively reviewed records of patients with mRCC treated with first-line TKIs at our institution between 2007 and 2012. The primary endpoint was the rate of early death within 1 year after first-line TKI administration. We determined statistically significant factors predicting early death by performing multiple logistic regression. The modified IMDC model 1 was developed using new variables in addition to the risk criteria of the IMDC model, and model 2 was developed using new variables irrespective of the risk classification of IMDC model.ResultsEarly mortality within 1 year of first-line TKI treatment was 19.7% (n = 98) in 462 patients. Although the C-index of the IMDC model for early death was 0.655, the C-index of model 1, which includes 5 variables (previous nephrectomy, body mass index, multiple metastases, previous metastasectomy, and serum albumin level) in addition to the Heng criteria, was 0.823. The C-index of model 2, which includes 7 variables (hemoglobin, neutrophil level, and the 5 variables of model 1) was 0.822. Of note, there was no significant difference in net reclassification index between the 2 models.ConclusionThis is the first study suggesting novel prediction models for early death less than 1 year in patients with mRCC treated with first-line TKI.     

Hesperidin Shows Protective Effects on Renal Function in Ischemia-induced Acute Kidney Injury (Sprague-Dawley Rats)

ObjectiveHesperidin is a well-known flavanone glycoside copiously found in sweet orange and lemon, which was recently reported to possess significant anti-inflammatory, analgesic, antifungal, antiviral, antioxidant, and anticancer activities. Ischemia-reperfusion (I/R) injury is a major problem after renal transplantation. Furthermore, inflammatory responses to I/R exacerbate the resultant renal injury. In the present study, we investigated whether hesperidin exhibits renoprotective effects against I/R-induced acute kidney injury in a rat model.MethodsWe fed Sprague-Dawley rats either hesperidin (100 mg/kg/d) or saline. One week later, ischemia was induced by bilateral renal pedicle occlusion for 30 minutes followed by reperfusion. The rats were randomly divided into 3 groups, which were treated as follows: 1. the sham operated group; 2. the I/R group; 3. the I/R-hesperidin groupResultsCompared to the sham group, the I/R group had higher expression of blood urea nitrogen and serum creatinine and lower expression of catalase, superoxide dismutase, glutathione peroxidase, antioxidants, and nitric oxide. Compared to the I/R group, the I/R-hesperidin group had higher expression of catalase, superoxide dismutase, glutathione peroxidase, antioxidant, and nitric oxide and lower expression of blood urea nitrogen and serum creatinine.ConclusionsHesperidin improved acute renal I/R injury through its antioxidant effects. These findings suggest that hesperidin is a potential therapeutic agent for acute ischemia-induced renal damage.     

隔药灸崔氏四花穴治疗小儿咳嗽变异性哮喘疗效观察及对机体免疫功能的影响

目的观察隔药灸崔氏四花穴治疗小儿咳嗽变异性哮喘的疗效及对机体免疫功能的影响。方法选择小儿咳嗽变异性哮喘患者90例,随机分为观察组和对照组,每组45例。观察组给予隔药灸崔氏四花穴治疗,对照组给予口服孟鲁斯特钠咀嚼片治疗,治疗6周后观察咳嗽症状评分、肺气道功能指标、血清嗜酸性粒细胞、嗜酸性粒细胞阳离子蛋白、免疫球蛋白E及CD^3﹢、CD^4﹢、CD^8﹢、CD^4﹢/CD^8﹢的变化,并统计临床疗效。结果观察组治疗后咳嗽症状评分,血清EOS、ECP及IgE水平,CD^4﹢、CD^8﹢、CD^4﹢/CD^8﹢水平均明显低于对照组(P<0.05);血清CD8﹢水平明显高于对照组(P<0.05)。观察组治疗后在肺气道功能指标(MEF75%,MEF50%,MEF25%)方面明显高于对照组(P<0.05)。观察组、对照组临床疗效总有效率分别为91.1%、75.6%,差异有统计学意义(P<0.05)。结论隔药灸崔氏四花穴可以有效改善小儿咳嗽变异性哮喘患者的咳嗽症状,提高小儿咳嗽变异性哮喘患者的免疫功能。